| miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting C Esau, S Davis, SF Murray, XX Yu, SK Pandey, M Pear, L Watts, ... Cell metabolism 3 (2), 87-98, 2006 | 2606 | 2006 |
| The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation V Tripathi, JD Ellis, Z Shen, DY Song, Q Pan, AT Watt, SM Freier, ... Molecular cell 39 (6), 925-938, 2010 | 2434 | 2010 |
| Nusinersen versus sham control in infantile-onset spinal muscular atrophy RS Finkel, E Mercuri, BT Darras, AM Connolly, NL Kuntz, J Kirschner, ... New England Journal of Medicine 377 (18), 1723-1732, 2017 | 2055 | 2017 |
| RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform CF Bennett, EE Swayze Annual review of pharmacology and toxicology 50 (1), 259-293, 2010 | 1529 | 2010 |
| Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43 M Polymenidou, C Lagier-Tourenne, KR Hutt, SC Huelga, J Moran, ... Nature neuroscience 14 (4), 459-468, 2011 | 1391 | 2011 |
| MicroRNA-143 regulates adipocyte differentiation C Esau, X Kang, E Peralta, E Hanson, EG Marcusson, LV Ravichandran, ... Journal of Biological Chemistry 279 (50), 52361-52365, 2004 | 1339 | 2004 |
| Nusinersen versus sham control in later-onset spinal muscular atrophy E Mercuri, BT Darras, CA Chiriboga, JW Day, C Campbell, AM Connolly, ... New England Journal of Medicine 378 (7), 625-635, 2018 | 1279 | 2018 |
| Antisense oligonucleotide modulation of multidrug resistance-associated protein E Baracchini, CF Bennett, NM Dean US Patent 5,801,154, 1998 | 1127 | 1998 |
| Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study RS Finkel, CA Chiriboga, J Vajsar, JW Day, J Montes, DC De Vivo, ... The Lancet 388 (10063), 3017-3026, 2016 | 1039 | 2016 |
| RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention CJ Donnelly, PW Zhang, JT Pham, AR Haeusler, NA Mistry, S Vidensky, ... Neuron 80 (2), 415-428, 2013 | 1031 | 2013 |
| Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. CF Bennett, MY Chiang, H Chan, JE Shoemaker, CK Mirabelli Molecular pharmacology 41 (6), 1023-1033, 1992 | 879 | 1992 |
| Pleiotropic cell-division defects and apoptosis induced by interference with survivin function F Li, EJ Ackermann, CF Bennett, AL Rothermel, J Plescia, S Tognin, ... Nature cell biology 1 (8), 461-466, 1999 | 868 | 1999 |
| Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis HB Kordasiewicz, LM Stanek, EV Wancewicz, C Mazur, MM McAlonis, ... Neuron 74 (6), 1031-1044, 2012 | 858 | 2012 |
| Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs C Lagier-Tourenne, M Polymenidou, KR Hutt, AQ Vu, M Baughn, ... Nature neuroscience 15 (11), 1488-1497, 2012 | 831 | 2012 |
| Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents: a comparative analysis TA Vickers, S Koo, CF Bennett, ST Crooke, NM Dean, BF Baker Journal of Biological Chemistry 278 (9), 7108-7118, 2003 | 787 | 2003 |
| Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model Y Hua, K Sahashi, F Rigo, G Hung, G Horev, CF Bennett, AR Krainer Nature 478 (7367), 123-126, 2011 | 777 | 2011 |
| Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion D Sareen, JG O’Rourke, P Meera, A Muhammad, S Grant, M Simpkinson, ... Science translational medicine 5 (208), 208ra149-208ra149, 2013 | 775 | 2013 |
| Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides RS Geary, D Norris, R Yu, CF Bennett Advanced drug delivery reviews 87, 46-51, 2015 | 773 | 2015 |
| Regulating gene expression through RNA nuclear retention KV Prasanth, SG Prasanth, Z Xuan, S Hearn, SM Freier, CF Bennett, ... Cell 123 (2), 249-263, 2005 | 759 | 2005 |
| Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model Y Hua, K Sahashi, G Hung, F Rigo, MA Passini, CF Bennett, AR Krainer Genes & development 24 (15), 1634-1644, 2010 | 749 | 2010 |
Frank RigoSenior Vice President, Ionis Pharmaceuticals在 ionisph.com 的电子邮件经过验证
